BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-29@pharmaconomics
DTSTAMP:20260707T034205Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:AZN Phase 3 — Anifrolumab
DESCRIPTION:Phase 3 trial results for Anifrolumab in Lupus Nephritis are due Feb 26\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT05138133\n\nTrack it: https://www.pharmaconomics.com/e/29
URL:https://www.pharmaconomics.com/e/29
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AZN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR